

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

VOLUNTARY ANNOUNCEMENT

This announcement is made by CStone Pharmaceuticals (the “**Company**”, and, together with its subsidiaries, the “**Group**”) on a voluntary basis.

As published on February 16, 2024, the Company is no longer an eligible stock on the Hang Seng Composite Index and with effect from March 4, 2024, the Company is no longer included on the Hong Kong Stock Connect.

Having made reasonable enquiries with respect to the Company as is reasonable in the relevant circumstances, save as disclosed above, the Company confirms that it is not aware of any reasons for the Movements or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The Company also confirms that the Group’s business operation remains normal, and that there is no material change to the business operation and financial position of the Group. The Company’s businesses are essentially going according to plan. Additional information concerning the Company’s business operations and financial position will be available in the Company’s annual results announcement, which is scheduled for late March, and in an investor presentation which the Company intends to convene following publication of the annual results announcement.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People’s Republic of China, March 4, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III, Mr. Xianghong Lin and Mr. Edward Hu as non-executive directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive directors.